Evidence map›Paper›PMID 34312462›Full record

Trial reportLeukemia2022

Decrease post-transplant relapse using donor-derived expanded NK-cells.

Stefan O Ciurea, Piyanuch Kongtim, Doris Soebbing, Prashant Trikha, Gregory Behbehani, Gabriela Rondon, Amanda Olson, Qaiser Bashir, Alison M Gulbis, Kaur Indreshpal and 10 more

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 5 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. CXCL10-induced chemotaxis ofMolecular therapy. Oncology · 2025
    Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Stefan O CiureaDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. sciurea@uci.edu.ORCID http://orcid.org/0000-0001-8597-3271
Piyanuch KongtimDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.
Doris SoebbingDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Prashant TrikhaAbigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Gregory BehbehaniDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amanda OlsonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-1669-0355
Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-4086-6453
Alison M GulbisDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kaur IndreshpalGMP Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katayoun RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roland BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kai CaoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew St MartinCenter for International Bone Marrow Transplant Research, Milwaukee, WI, USA.
Steven DevineNational Marrow Donor Program, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-7731-759X
Mary HorowitzCenter for International Bone Marrow Transplant Research, Milwaukee, WI, USA.
Marcelo PasquiniCenter for International Bone Marrow Transplant Research, Milwaukee, WI, USA.
Dean A Lee *Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Richard E Champlin *Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-4314-5037
The University of Texas MD Anderson Cancer Center · USNational Marrow Donor Program · USNationwide Children's Hospital · USThe Ohio State University · USUniversity of California, Irvine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 1990 to 2014
$41.8M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation (HSCT). Three doses of donor NK cells (1 × 10

Indexed as

AdolescentAdultAgedCase-Control StudiesFemaleFollow-Up StudiesHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansKiller Cells, NaturalMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisSurvival RateTransplantation Conditioning

Identifiers

PMID34312462
PMCPMC8727305
OpenAlexW3183272916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.